Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy.

BioMed research international - 1 Jan 2017

Viale Giulia, Trapani Dario, Curigliano Giuseppe

Abstract excerpt

Immunotherapy has revolutionized cancer treatment. Immune-checkpoint inhibitors, on balance, showed a favorable efficacy/toxicity profile with durable response in different cancer types. No predictive biomarker has been validated thus far to select patients who would benefit from therapy. Among the candidate predictive biomarkers, mismatch repair status of the tumor is currently one of the most promising. Indeed,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Clinical Trials as Topic
Share to DNA Mismatch Repair

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy

Share to Inflammation

Share to Microsatellite Instability

Share to Mutation

Share to Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 28770222
DOI: 10.1155/2017/4719194
PMCID: PMC5523547

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy.PMID 28770222Read ↗

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacySemantic proximity Read ↗

The role of DNA mismatch repair in immunotherapy of human cancer.Semantic proximity Read ↗

Biomarkers for immune therapy in colorectal cancer: mismatch-repair deficiency and othersSemantic proximity Read ↗

Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours?Semantic proximity Read ↗

Advances and prospects of biomarkers for immune checkpoint inhibitorsSemantic proximity Read ↗

Predictive Biomarkers for Immunotherapy Response Beyond PD-1/PD-L1.Semantic proximity Read ↗

The Clinical Impact of the Genomic Landscape of Mismatch Repair–Deficient CancersSemantic proximity Read ↗

Microsatellite Instability: A Predictive Biomarker for Cancer Immunotherapy.Semantic proximity Read ↗

Microsatellite instability status predicts response to anti-PD-1/PD-L1 therapy regardless the histotype: A comment on recent advancesSemantic proximity Read ↗

Immune Checkpoint Inhibition in Metastatic Colorectal Cancer Harboring Microsatellite Instability or Mismatch Repair DeficiencySemantic proximity Read ↗

Beyond Tumor PD-L1: Emerging Genomic Biomarkers for Checkpoint Inhibitor ImmunotherapySemantic proximity Read ↗

Predictive biomarkers for immune checkpoint inhibition for patients with colorectal cancer: a comprehensive review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.